Clinical Practice Guidelines for the management of locally advanced ...

More documents

Recommendations

Info

cardiovascular mortality 19, 54, 55, 56 care plans 98, 100 carers and palliative care 100 and symptom control 98 Carers Australia 140 castration, side effects 18–23, 53–56 castration-resistant prostate cancer 136 and bisphosphonates 78–83 and bone pain 80–81 chemotherapy 88–90 defined 75 dietary supplements 116 docetaxel 78, 89–90, 116 emerging therapies 116 hormone manipulations continuing after hormone refractory 78 second-line 75–77 and prostate specific antigen (PSA) 75 and radiotherapy 84–88 recommendations 77, 78, 82, 83, 85, 86, 88, 90 with rise in prostate specific antigen (PSA) 88–90 CAT scan see computed tomography (CT) chemotherapy 88 biochemical relapse 115 castration-resistant prostate cancer 88–90 evidence summaries 90 hormone-naïve metastatic bone prostate cancer 88 metastatic disease 88–90 recommendations 90 see also docetaxel chlormadinone acetate 54 classification pathological 129 of prostate tumours 129–132 rules of 129 clodronate 79, 80, 81, 83 cognitive behavioual interventions 6–7 cognitive function 55 combined androgen blockage (CAB) 133, 13 locally advanced disease 18, 19 metastatic disease 53–54 communication and literacy levels 111 complementary and alternative therapies 105–108, 136 evidence summaries 108 recommendations 105, 108 complementary medicine 105 complete remission 136 computed tomography (CT) 1, 136 confidence intervals 136 coping strategies 136 counselling, and androgen deprivation therapy (ADT) 50 cryotherapy 48 cyproterone acetate 51, 54, 55, 57 cystitis 136 cystoscopes 136 151 Index
death, at home 99–100 decision making interventions to improve 3–4 and literacy levels 111 palliative care 98 shared 2 depression 10–12, 136 dexamethasone 64–65 diagnosis 1 diarrhoea 55, 56, 57 dietary interventions 106–108 biochemical relapse 115 and quality of life 7–9 dietary supplements 106–108 castration-resistant prostate cancer 116 diethylstillbestrol (DES) 106, 116 digital rectal examination (DRE) 136 dissemination 133 distant metastasis, classification of 130 docetaxel biochemical relapse 115 castration-resistant prostate cancer 78, 89–90, 116 locally advanced disease 115 metastatic disease 115 side effects 89–90 dry ejaculation 133 dual energy x-ray absorptiometry (DEXA) 21 education 3–4, 5 effectiveness 137 ejaculate 137 ejaculation dry 136 retrograde 140 ellagic acid 106, 107 emerging therapies 115–116 biochemical relapse 115 castration-resistant prostate cancer 116 locally advanced disease 115 metastatic disease 115–116 end-of-life care 97, 98, 99–100 estramustine 89–90, 107 ethnicity 111 evaluation 137 evidence 137 levels of vii–viii, 120–121 evidence summaries biochemical relapse 49 bisphosphonates 80, 82 chemotherapy 90 complementary and alternative therapies 108 hormone manipulations for castrate resistance disease 77 locally advanced disease androgen deprivation therapy (ADT) 17, 18, 20, 23, 24, 29, 31 radiotherapy 26, 27, 29, 31, 36, 37, 38 surgery 32, 34 metastatic disease Clinical practice guidelines for the management of locally advanced and metastatic prostate cancer 152
Page 1:
Clinical Practice Guidelines for th
Page 4 and 5:
4 Biochemical relapse .............
Page 6 and 7:
FOREWORD The management of prostate
Page 8 and 9:
SUMMARY OF CLINICAL PRACTICE RECOMM
Page 10 and 11:
SUMMARY OF RECOMMENDATIONS Chapter
Page 12 and 13:
Chapter Recommendations Grade Refs
Page 14 and 15:
Page 16 and 17:
Page 18 and 19:
Page 20 and 21:
1 INTRODUCTION 1.1 Natural history
Page 22 and 23:
2 PSYCHOSOCIAL CARE The diagnosis a
Page 24 and 25:
2.2 Effect of psychological and cog
Page 26 and 27:
Evidence summary Level References T
Page 28 and 29:
Recommendation Men with advanced pr
Page 30 and 31:
An Australian cross-sectional study
Page 32 and 33:
10. Dunn J, et al. A review of peer
Page 34 and 35:
41. Sharpley CF, Christie DRH. An a
Page 36 and 37:
different treatments from different
Page 38 and 39:
Evidence summary Level References I
Page 40 and 41:
Evidence summary Level References F
Page 42 and 43:
Despite these reservations and the
Page 44 and 45:
For non-metastatic disease there we
Page 46 and 47:
Evidence summary Level References T
Page 48 and 49:
monotherapy for low-to-intermediate
Page 50 and 51:
Evidence summary Level References M
Page 52 and 53:
for surgery, suggesting that surger
Page 54 and 55:
Microscopic fully resected node pos
Page 56 and 57:
All three trials demonstrated impro
Page 58 and 59:
Evidence summary Level References B
Page 60 and 61:
of an international multicentre ran
Page 62 and 63:
45. Melton LJ, III, Alothman KI, Kh
Page 64 and 65:
76. Little DJ, Kuban DA, Levy LB, Z
Page 66 and 67:
105. Thompson IM, Tangen CM, Parade
Page 68 and 69:
4.2 Androgen deprivation therapy (e
Page 70 and 71:
Evidence summary Level References F
Page 72 and 73:
therapy since such studies would be
Page 74 and 75:
apparent in trials comparing CAB wi
Page 76 and 77:
QLQ instrument published by Cleary
Page 78 and 79:
Note: Larger well-powered studies h
Page 80 and 81:
Eight trials examined acute toxicit
Page 82 and 83:
half of patients experienced pain r
Page 84 and 85:
olus) in addition to radiotherapy a
Page 86 and 87:
References 1. Seidenfeld J, Samson
Page 88 and 89:
Cooperative Group. Scandinavian Jou
Page 90 and 91:
Oncology Group, TROG 96.05). Radiot
Page 92 and 93:
trial. European Journal of Cancer 1
Page 94 and 95:
6 CASTRATION-RESISTANT PROSTATE CAN
Page 96 and 97:
the median overall survival for pat
Page 98 and 99:
There are two points regarding bisp
Page 100 and 101:
with bone pain at study entry. At n
Page 102 and 103:
Recently, there have been reports o
Page 104 and 105:
of these studies 56, 58 and in the
Page 106 and 107:
Side effects (toxicity) As these ra
Page 108 and 109:
hydrocortisone respectively. Tannoc
Page 110 and 111:
5. Manikandan R, Srirangam SJ, Pear
Page 112 and 113:
33. Elomaa I, Kylmala T, Tammela T
Page 114 and 115:
60. Janknegt RA, Abbou CC, Bartolet
Page 116 and 117:
physiotherapists, occupational ther
Page 118 and 119:
7.5 Q2: Symptom control There was e
Page 120 and 121: Informal or family caregivers deriv
Page 122 and 123: 8. Hughes SL, Weaver FM, Giobbie-Hu
Page 124 and 125: 8 COMPLEMENTARY AND ALTERNATIVE (UN
Page 126 and 127: corresponding benefit in obstructiv
Page 128 and 129: 3. Eisenberg DM, Kessler RC, Van Ro
Page 130 and 131: areas of the state were more likely
Page 132 and 133: 8 Miller DC, Litwin MS, Bergman J,
Page 134 and 135: 10 EMERGING THERAPIES It is impossi
Page 136 and 137: APPENDIX 1 GUIDELINE DEVELOPMENT PR
Page 138 and 139: study type. Studies published befor
Page 140 and 141: Grade of recommendation Description
Page 142 and 143: 2. National Health and Research Cou
Page 144 and 145: Dr Carole Pinnock AM Principal rese
Page 146 and 147: Surgery Professor Villis Marshall A
Page 148 and 149: APPENDIX 3 TNM CLASSIFICATION OF PR
Page 150 and 151: Summary Prostate T1 T2 T3 T4 N1 M1a
Page 152 and 153: APPENDIX 4 ABBREVIATIONS AND GLOSSA
Page 154 and 155: Glossary Actuarial survival A metho
Page 156 and 157: Effectiveness The extent to which a
Page 158 and 159: Lymph nodes Small, generally pea-si
Page 160 and 161: Each stage is divided into subgroup
Page 162 and 163: APPENDIX 6 - ORGANISATIONS WHICH PR
Page 164 and 165: Consultant Urologist, Royal Brisban
Page 166 and 167: No conflict of interest to declare.
Page 168 and 169: Index to Clinical practice guidelin
Page 172 and 173: androgen deprivation therapy (ADT)
Page 174 and 175: and surgery 32-34 survival 18 toxic
Page 176 and 177: and chemotherapy 89-90 see also bon
Page 178 and 179: spinal cord compression 62-63 see a
Page 180 and 181: systemic 141 Tasmania Association f
show all

Clinical Practice Guidelines for the management of locally advanced ...

Create successful ePaper yourself

Delete template?

Save as template?